• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry

    Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    "It is with great pleasure that we welcome Derrick as the latest addition to our leadership team," said Matt Brokaw, CEO of Aerin Medical. "With a proven track record of financial leadership and a wealth of operating expertise, Derrick will play a pivotal role in accelerating our pursuit of a new standard of care for millions of untreated sufferers of ENT conditions."

    Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation (NASDAQ:LUNG) where he scaled the finance organization and led the company through significant growth and a successful IPO. Before that, he led strategy and corporate development at iRhythm Technologies (NASDAQ:IRTC). Previously, Sung spent seven years on Wall Street as a senior equity research analyst covering the medical devices sector, directed marketing and business development for Boston Scientific's Neuromodulation division, led management consulting engagements at the Boston Consulting Group, and designed heart catheters as an R&D engineer for Guidant Corporation. He received his Ph.D. in bioengineering from the University of California, San Diego, his Master of Business Administration from San Diego State University, and his Bachelor of Science degree in mechanical engineering from Stanford University.

    "I am excited to join the exceptional team at Aerin Medical as we embark on the next phase of growth," said Sung. "Fueled by compelling fundamentals and a rare financial profile, we are poised to achieve remarkable success."

    About Aerin Medical

    Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 100,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231120576987/en/

    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IRTC
    $LUNG

    CompanyDatePrice TargetRatingAnalyst
    iRhythm Technologies Inc.
    $IRTC
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    Pulmonx Corporation
    $LUNG
    3/10/2025$17.00Buy
    D. Boral Capital
    Pulmonx Corporation
    $LUNG
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    iRhythm Technologies Inc.
    $IRTC
    12/3/2024$86.00Equal Weight
    Wells Fargo
    iRhythm Technologies Inc.
    $IRTC
    10/4/2024$78.00Neutral
    Goldman
    iRhythm Technologies Inc.
    $IRTC
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    Pulmonx Corporation
    $LUNG
    6/4/2024$12.00Buy
    Lake Street
    Pulmonx Corporation
    $LUNG
    2/23/2024$16.00 → $14.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $IRTC
    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      6/5/25 8:39:08 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      11/5/24 11:59:44 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      8/22/24 6:41:17 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $IRTC
    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025

      REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Wednesday, July 30, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive

      7/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

      MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel

      7/15/25 8:45:00 AM ET
      $ABT
      $DXCM
      $IRTC
      $TNDM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities

    $IRTC
    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iRhythm upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

      5/2/25 8:03:46 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • D. Boral Capital initiated coverage on Pulmonx with a new price target

      D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

      3/10/25 8:07:21 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx downgraded by Citigroup with a new price target

      Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously

      12/11/24 7:54:19 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $IRTC
    $LUNG
    SEC Filings

    See more
    • iRhythm Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

      7/7/25 5:16:57 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Pulmonx Corporation

      144 - Pulmonx Corp (0001127537) (Subject)

      6/13/25 11:47:38 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Pulmonx Corporation

      144 - Pulmonx Corp (0001127537) (Subject)

      6/12/25 5:24:33 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $IRTC
    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcginnis Karen K was granted 2,035 shares (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      7/8/25 4:23:16 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Oboyle Kevin C was granted 2,035 shares (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      7/8/25 4:22:49 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Mcginnis Karen K

      3 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      7/8/25 4:21:47 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/14/24 7:47:49 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 12:54:21 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/12/24 10:34:16 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $IRTC
    $LUNG
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

      REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

      4/2/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

      iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

      2/29/24 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

      REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

      2/21/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $IRTC
    $LUNG
    Financials

    Live finance-specific insights

    See more
    • Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025

      REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Wednesday, July 30, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive

      7/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care